The future of specialty pharmacy is not coming. It is already here, accelerating in real time, and from what I’m hearing across the market, it is demanding a new level of leadership, interoperability, patient engagement, distribution strategy, and technology maturity. At the 2026 Asembia “Access to Specialty Pharmacy” meeting in Las Vegas, I had the chance to connect with leaders who are shaping the next chapter of this sector alongside Nicolle McClure, CEO of Finch Marketing. Together, we were there to listen, document, and spotlight the voices moving specialty pharmacy forward through our Pharmacy Podcast Network press coverage series. What became clear is that specialty pharmacy is no longer just a support channel for complex medications. It is becoming one of the most strategic care-delivery infrastructures in all of healthcare.
Convergence. From my perspective, from documenting the pharmacy profession through podcasting since 2009, the specialty pharmacy story is really about convergence. Advanced therapies, personalized medicine, biologics, digital navigation, AI, interoperability, payment innovation, and patient support are all colliding at once. The market is growing because healthcare is treating more chronic, rare, and complex disease states with highly specialized therapies. But growth alone is not the story. The real story is transformation. Specialty pharmacy is being forced to evolve into something more coordinated, more data-driven, and more deeply connected to patient outcomes than ever before.
Harry Travis, President of The Travis Group, framed one of the most urgent questions in this transformation with his focus on whether AI will revolutionize pharmacy before it harms us. That is the right tension to examine. AI is not a side topic anymore. It is central to how specialty pharmacy will scale decision-making, improve visibility, and manage complexity. But Harry’s framing also reminds us that innovation without governance can create real risk. Specialty pharmacy leaders are being asked to adopt AI fast, but they must also protect patients, preserve trust, and ensure the technology serves care rather than replacing human judgment.
Joe DePinto, Head of Cell, Gene, and Advanced Therapies at McKesson, brought sharp clarity to the operational realities of the future. He explained that cell and gene therapies are not typical products a health system uses day to day. These therapies require trusted partners, sophisticated services, and an industrialized standard for delivery. That insight matters because the future of specialty pharmacy will increasingly be defined by whether organizations can operationalize innovation, not just admire it. Joe’s point is simple and powerful: when the science is complex, the service model has to be equally advanced.
Bret Paulson, VP of Market Access & Channel Strategy at Otsuka Pharmaceuticals, joined that broader conversation around the future outlook for payers and providers. His inclusion in that discussion signals how market access strategy is becoming inseparable from specialty pharmacy’s future. The specialty ecosystem is being shaped not only by clinical excellence, but by channel design, reimbursement architecture, and payer-provider alignment that determines whether patients can actually reach therapy in time.
Michael Einodshofer, Chief Growth Officer at Free Market Health, focused on the future of digital navigation for specialty pharmacy, joined by Daniel Knecht of Emblem Health. Their conversation points to a major reality: access is no longer just about benefits and dispensing. It is about navigation. Specialty pharmacy’s future will reward organizations that reduce friction, simplify the patient journey, and create smarter ways for patients, providers, and payers to move through complex treatment pathways. In the document, Daniel Knecht is identified with Emblem Health, though no formal title is provided there.
Michael Oleksiw, CEO of Pleio, added another vital layer by exploring how emotional and social factors quietly undermine adherence. That is one of the most overlooked truths in specialty pharmacy. Even the best therapies fail if human behavior is ignored. Michael’s insight around AI-powered visibility into real-world patient behaviors is especially relevant as oral GLP-1 therapies expand rapidly. Traditional support programs are not keeping pace, and the result is lost revenue for manufacturers and unmet needs for patients. His message is that the future belongs to organizations that understand the patient as a person, not just a prescription.
Meghna Misra, VP of Product at Claritas Rx, pushed the AI conversation into practical territory. Her focus is not hype, but utility. She described how AI can cut through healthcare fragmentation, improve patient visibility, proactively identify risk, unblock therapies like CAR-T and rare disease treatments, and embed insights into workflows without disrupting care teams. That is exactly the kind of grounded innovation specialty pharmacy needs. The future is not about adding another dashboard. It is about making intelligence actionable for the people already doing the work.
Pooja Babbrah, Strategy and Industry Alignment at NCPDP, delivered one of the most important structural insights of all: interoperability is not just a technology issue. It is a recognition issue. Pharmacists must be fully acknowledged as vital members of the care team. Her emphasis on health information exchanges, TEFCA, and QHINs points to a future where pharmacists can access and share clinical data like any other provider. That would be a breakthrough for care coordination and patient outcomes. Specialty pharmacy cannot reach its full potential if pharmacists are still boxed out of the broader data ecosystem.
Allison Arant, Senior Vice President of Client Development and Marketing at Clearway Health, highlighted the future of specialty pharmacy as partnership-driven and inclusive. Her message centered on helping clients build, strengthen, and elevate specialty pharmacy programs so they can improve access to care and support vulnerable patients. Rooted in Clearway Health’s origin at Boston Medical Center, her insight reflects a future where hospital and health system partnerships become essential to sustainable specialty pharmacy growth. This is not just about business development. It is about building care models that remove barriers and get medications to patients on time.
Sheila Arquette, CEO of NASP, was connected in the document to one of the biggest market disruptors on the horizon: TrumpRx and the broader direct-to-consumer disruption of drug access. The implications are serious. Disintermediation, data fragmentation, safety gaps, and the commoditization of specialty drugs all threaten the high-touch model that specialty pharmacy depends on. Her section underscores a crucial warning for the future: if specialty drugs are pushed through low-touch access channels optimized for price and convenience alone, patient outcomes and total cost of care may worsen.
Ben Heiser, SVP and CEO of Lumicera Health Services, described a future shaped by transparency, efficiency, and sustainability through Clarventa. His vision applies cost-plus principles to purchasing and supply chain functions, bringing more predictability to a system often clouded by opacity. That is a big deal. Specialty pharmacy’s future is not only clinical and digital. It is financial and operational. If transparency improves upstream, pharmacies and patients downstream stand to benefit.
Alan Oustaev, Chief Operating Officer of Invictus Pharmacy, offered one of the boldest signals of where innovation may go next: cryptocurrency payments and blockchain-enabled prescription transaction infrastructure. Whether the market embraces it broadly or cautiously, his vision is about speed, transparency, security, and auditable financial flows across the drug channel. It is unconventional, yes, but it reflects a larger truth: specialty pharmacy is now attracting ideas from far beyond traditional pharmacy operations.
Cameron Olig, CMO, Chief Commercial Officer, and Board Member at Prescryptive, spoke to growing employer demand for clinically rigorous and economically sustainable GLP-1 access. His insight centers on an employer-direct ecosystem that aligns incentives among employers, manufacturers, centers of excellence, and care operators. That model hints at a future where access pathways become more direct, more accountable, and more outcomes-oriented.
The bottom line is this: specialty pharmacy is becoming the command center for complex care. The winners in this next era will be the organizations that combine high-touch care with high-tech capability, protect the pharmacist’s role in coordinated care, embrace transparency, and never lose sight of the patient journey. From AI to interoperability, from digital navigation to supply chain clarity, from adherence science to access disruption, the future of specialty pharmacy is being written right now by leaders willing to rethink the model. And as I’ve learned after years behind the mic, when pharmacy speaks with boldness, collaboration, and purpose, the profession doesn’t just adapt. It leads.
Todd Eury
CEO, Pharmacy Podcast Network
www.pharmacypodcast.com
Related reading: Explore more coverage in our Innovation section and browse the latest analysis on Dispense Times.
